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ABSTRACT Cryptococcal meningoencephalitis is a rapidly lethal infection in immu-
nocompromised patients. Induction regimens are usually administered for 2 weeks.
The shortest effective period of induction therapy with liposomal amphotericin B
(LAMB) is unknown. The pharmacodynamics of LAMB were studied in murine and
rabbit models of cryptococcal meningoencephalitis. The concentrations of LAMB in
the plasma and brains of mice were measured using high-performance liquid chro-
matography (HPLC). Histopathological changes were determined. The penetration of
LAMB into the brain was determined by immunohistochemistry using an antibody
directed to amphotericin B. A dose-dependent decline in fungal burden was ob-
served in the brains of mice, with near-maximal efﬁcacy achieved with LAMB at 10
to 20 mg/kg/day. The terminal elimination half-life in the brain was 133 h. The phar-
macodynamics of a single dose of 20 mg/kg was the same as that of 20 mg/kg/day
administered for 2 weeks. Changes in quantitative counts were reﬂected by histo-
pathological changes in the brain. Three doses of LAMB at 5 mg/kg/day in rabbits
were required to achieve fungicidal activity in cerebrospinal ﬂuid (cumulative area
under the concentration-time curve, 2,500 mg · h/liter). Amphotericin B was visible
in the intra- and perivascular spaces, the leptomeninges, and the choroid plexus.
The prolonged mean residence time of amphotericin B in the brain suggests that
abbreviated induction regimens of LAMB are possible for cryptococcal meningoen-
cephalitis.
KEYWORDS liposomal amphotericin B, pharmacokinetics, pharmacodynamics,
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Cryptococcal meningitis is a common and frequently lethal disease in patients withHIV/AIDS (1). Rapid fungicidal activity in cerebrospinal ﬂuid (CSF) is associated with
better clinical outcomes and improved survival (2). Amphotericin B deoxycholate
(DAMB) is the most potent amphotericin B formulation on a milligram-milligram basis
(3, 4). While effective, DAMB is toxic and associated with signiﬁcant infusion-related
toxicity, nephrotoxicity, and anemia (5, 6). Furthermore, DAMB is not orally bioavailable
and must be injected. The need for rapid, reliable monitoring for side effects and for
intravenous administration means that amphotericin B-based treatment is simply not
possible in many resource-poor settings. Hence, the best current therapy cannot be
administered to patients in many countries where the prevalence of cryptococcal
meningitis is the highest. In these cases, the only alternative agent is ﬂuconazole, but
even with the use of high doses (800 to 1,200 mg/day), the fungicidal activity in CSF
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and clinical outcomes are suboptimal (7, 8). Alternative approaches are urgently
required.
There is surprisingly little evidence for the use of liposomal amphotericin B (LAMB)
for cryptococcal meningitis. Preclinical and clinical data suggest that 3 to 6 mg/kg of
body weight/day is a safe and effective regimen (9, 10). Typically, the duration of
amphotericin B-based induction regimens is 2 weeks, based primarily on surrogate
mycological markers of early fungicidal activity such as CSF sterilization (11, 12). The
shortest duration of LAMB that is maximally effective is not known. We recently
demonstrated that an abbreviated course of DAMB (3 days) may be as effective as 2
weeks of therapy (13) and that short courses of DAMB (in combination with ﬂucona-
zole) are associated with rapid clearance of the CSF in patients with cryptococcal
meningitis (14). Thus, there are a precedent and a rationale for examining the safety
and efﬁcacy of abbreviated regimens of LAMB as induction therapy for cryptococcal
meningitis.
Here, we used two previously described (15, 16) and well-characterized laboratory
animal models of cryptococcal meningitis to study the pharmacodynamics of abbre-
viated courses of liposomal amphotericin B. Our principal goal was to provide the
experimental evidence underpinning phase II and III clinical trials examining the
efﬁcacy of abbreviated regimens of LAMB.
RESULTS
Dose exposure-response relationships in mice. Liposomal amphotericin B was
well tolerated in mice with no observed toxicity following rapid intravenous (i.v.)
injection. There was a clear dose-response relationship with doses of 0.5 to 20 mg/kg/
day. Fungicidal activity was not observed (i.e., we did not observe a decline in the
number of log10 CFU/g following daily therapy). Rather, a fungistatic effect was seen
whereby the infection at the time of drug administration 24 h postinoculation was
stabilized. Near-maximal antifungal activity was observed following treatment with 10
to 20 mg/kg/day and with an AUC/MIC ratio of approximately 100 (Fig. 1).
A profound and durable antifungal effect was apparent following a single dose of 20
mg/kg in mice (Fig. 2). There was no evidence of signiﬁcant fungal regrowth after 240
h of observation. The persistent antifungal effect may be explained by the long terminal
half-life of amphotericin B in the plasma and cerebrum (113 h) (Fig. 3).
Histopathology and immunohistochemistry in mice. The persistent antifungal
effect evident from the log10 CFU/g data were mirrored by the histopathological
ﬁndings shown in Fig. 4. In mice receiving vehicle only, cryptococcal meningoenceph-
alitis manifested as a multifocal disease with cyst-like cavities ﬁlled with multiple
encapsulated organisms approximately 6 to 10 m in diameter. There was no evidence
of an inﬂammatory component within or around the cavities.
Mouse livers (harvested from mice receiving a total cumulative liposomal ampho-
tericin B dose of 225 mg/kg) were used as the positive-control tissue in all amphotericin
B localization experiments. Moderate to marked staining of frequent Kupffer cells was
observed in the positive-control tissue. All other tissue elements were negative. There
was no staining of Kupffer cells when a species-, isotype-, and concentration-matched
negative-control antibody (rabbit IgG) was substituted for the rabbit anti-AMB reagent.
Kuppfer cells in control mouse liver tissue that received 5% dextrose did not stain with
rabbit anti-AMB reagent.
There was differential penetration of amphotericin B into the brain (Fig. 5). Staining
was apparent early (i.e., 1 h after dose) and in both intravascular and perivascular
spaces, suggesting that the drug crossed the blood-brain barrier. Staining was espe-
cially prominent in blood vessels in the leptomeninges and choroid plexus, as well as
small cerebral capillaries. Staining was both extra- and intracellular. Granular extracel-
lular staining was observed in and surrounding blood vessels. Intracellular cytoplasmic
staining was observed in mononuclear/microglial cells. Positive circulating mononu-
clear cells (presumptive monocytes) were identiﬁed in cerebral capillaries. Additional
extracellular staining was observed in the ventricular system associated with the
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ependymal lining, suggesting entry into the CSF. In contrast, staining was not observed
in the normal cerebral tissue or in residual cryptococcomas after 10 days of treatment
with LAMB at doses of 10 or 20 mg/kg/day.
Mathematical PK-PD model in mice. The ﬁt of the mathematical model to the
combined murine pharmacokinetic-pharmacodynamic (PK-PD) data set was accept-
able, even though ﬁtting was difﬁcult. The estimates for the parameters are summa-
rized in Table 1. The principal challenge was modeling the depot-like effect of LAMB in
the brains of mice in which low drug concentrations were observed to have exerted an
antifungal effect that lasted well beyond the time that liposomal amphotericin B
concentrations were detectable.
FIG 1 Pharmacodynamics of LAMB in cohorts of mice receiving 0.5 (B), 3 (C), 10 (D), and 20 (E) mg/kg/day i.v. The AUC/MIC ratio at steady state versus the
observed fungal density at the end of the experiment (time  240 h) is shown in panel F. All data are means  standard deviations of results from groups
of three mice.
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PK-PD relationships in rabbits. The mean parameter values best accounted for the
observed PK data. The parameter values were as follows: clearance of drug from the
central compartment (CLS), 0.018  0.008 liters/h; ﬁrst-order rate constant connecting
the central and peripheral compartments (Kcp), 10.37  0.416 h1; ﬁrst-order rate
constant connecting the peripheral and central compartments (Kpc), 26.09  0.96 h1;
ﬁrst-order rate constant (K), 0.093  0.04 h1; initial volume (Vini), 4.717  0.233 liters;
and ﬁnal volume (Vﬁn), 0.003  0.002 liters. The coefﬁcients of determination for the
linear regression before and after the Bayesian step were 0.87 and 0.98, respectively,
and in both cases, the intercept and slope approximated zero and one, respectively.
The pharmacodynamics data in rabbits similarly illustrated the potential utility of
abbreviated LAMB induction but differed somewhat from those observed in mice. A
single dose of LAMB at 5 mg/kg appeared fungistatic only up to 264 h and did not
provide a durable response in the CSF or cerebrum (Δlog10 CFU/g  1.9  1.2 and
3.2  0.5, respectively), despite a higher estimated AUC from 0 to 24 h (AUC0–24) than
that in mice receiving a single dose of 20 mg/kg (820 15 versus 580 30 mg · h/liter).
Three doses of LAMB at 5 mg/kg administered every 24 h (and commencing 48 h
postinoculation) induced a prompt decline in fungal burden in the CSF and cerebrum
(Δlog10 CFU/ml  2.8  0.8 and 0.1  0.4, respectively). This regimen produced a
cumulative total AUC48–120 of 2,499 mg · h/liter. The effect of this abbreviated regimen
in rabbits was comparable to that achieved with daily therapy (Fig. 6).
FIG 2 Pharmacodynamics of vehicle control (A) and LAMB (B) following the administration of a single
dose of 20 mg/kg i.v. to mice with cryptococcal meningoencephalitis. Data are the means  standard
deviations of results from groups of three mice. The solid line represents the ﬁt of the mathematical
PK-PD model (parameters summarized in Table 1). The black arrow denotes the time of drug adminis-
tration relative to inoculation (which occurred at time zero).
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The exposure-response relationships in the cerebra of rabbits were similar. The
fungal densities for control rabbits and for rabbits receiving 5 mg/kg once, 5 mg/kg/day
for 3 days, and 5 mg/kg/day were 5.92 0.55, 5.21 1.20, 2.43 1.23, and 2.47 0.70
log10 CFU/g (mean  standard deviation), respectively. Thus, in comparison to the
murine studies, 1 day of therapy was required in rabbits to achieve fungicidal activity
in the cerebrum and CSF.
PK-PD targets and bridging studies. A human regimen of liposomal amphotericin
B of 4 mg/kg/day produces an AUC0–24 at steady state of 190 mg · h/liter. As can be
seen in Fig. 1F, this is associated with near-maximal antifungal efﬁcacy in mice receiving
daily liposomal amphotericin B. A single dose of 20 mg/kg in mice (AUC0–24, 550 to 600
mg · h/liter) also produced near-maximal antifungal activity. The bridging study in
FIG 3 Pharmacokinetics of LAMB in murine plasma (red line and red data points) and cerebrum (black
line and black data points) in cohorts of mice infected with Cryptococcus neoformans receiving LAMB at
20 mg/kg once i.v. (24 h postinoculation). All data are means  standard deviations of results from
groups of three mice. The terminal half-life in the plasma and cerebrum is approximately 133 h.
FIG 4 Representative cross-sections of brains from mice receiving vehicle control, LAMB at 20 mg/kg/day
i.v., and LAMB at 20 mg/kg once i.v. Each section was stained with an anticryptococcal antibody and then
counterstained with hematoxylin. Treatment was initiated at the end of day 1 (i.e., 24 h postinoculation).
There are multiple cryptococcomas at the end of day 7 in untreated controls. In contrast, there are
relatively few and exceedingly small lesions in the two treatment groups.
Abbreviated Induction for Cryptococcal Meningitis Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e00090-17 aac.asm.org 5
AQ: H
C
O
L
O
R
C
O
L
O
R
C
O
L
O
R
C
O
L
O
R
zac-aac/zac00617/zac6192d17z xppws S3 3/23/17 14:08 4/Color Fig: 3,4,5 ArtID: 00090-17 DOI:10.1128/AAC.00090-17CE: MAR
rabbits suggested that a single dose of 5 mg/kg (AUC, 833 mg · h/liter) was insufﬁcient
to achieve fungicidal activity. Rather, a total of three doses of 5 mg/kg/day (cumulative
AUC, 2,499 mg · h/liter) was required to achieve fungicidal activity in the CSF. Thus,
there was a degree of discordance between the pharmacodynamic targets from mice
and rabbits, with the latter requiring slightly more drug exposure to achieve the same
effect.
DISCUSSION
Amphotericin B is the most potent agent for induction therapy against Cryptococcus
neoformans, and the combination with ﬂucytosine results in the most rapid overall
decline in fungal burden (17). This study suggests that abbreviated regimens of
FIG 5 Distribution of LAMB in the central nervous system. All mice received LAMB at 20 mg/kg i.v. In each panel,
black arrows indicate areas of staining of amphotericin B. (A) LAMB staining in the choroid plexus (extracellular and
within a macrophage); (B) positive LAMB staining within a mononuclear cell in a thin-walled cerebral capillary; (C)
positive staining in a perivascular location, adjacent to a thick-walled small arteriole; (D) LAMB staining in CSF
associated with the apical surface of ependymal cells, cerebral aqueduct. Scale bars, 5 (A, B, and D) and 25 (C) m.
TABLE 1 Parameters from the population PK-PD model from micea
Parameter (unit)
Value
Mean Median SD
CLS (liters/h) 0.00082 0.00094 0.00018
Vol (liters) 0.003 0.0027 0.0019
Kcp (h1) 11.99 10.52 9.94
Kpc (h1) 15.70 23.33 11.41
Kcb (h1) 0.16 0.22 0.013
Kbc (h1) 0.034 0.01 0.038
Kg max (log10 CFU/g/h) 0.096 0.084 0.033
Hg 7.96 7.72 6.00
C50 g (mg/liter) 0.088 0.056 0.100
Popmax (CFU/g) 23,785,100 57,435,030 249,007
Vm (liters) 0.72 0.94 0.37
Initial condition (CFU/g) 186 207 133.97
aEstimates for the mean, median, and standard deviation (SD) are shown. See the text for descriptions of
parameters.
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liposomal amphotericin B may be feasible. This is primarily a function of a favorable
pharmacokinetic proﬁle with long terminal elimination phases in both the plasma and
brain (half-life [t1/2], 133 h).
The apparent discordance between plasma concentrations of liposomal amphoter-
icin B and its persistent anticryptococcal activity in the central nervous system (CNS) of
both mice and rabbits is of considerable interest, although the underlying mechanism
driving this phenomenon is not entirely clear. One possibility is that there are a limited
number of binding sites for amphotericin B in the CNS. Once occupied, amphotericin
B does not readily disengage from its binding sites, leading to a pharmacologically
active depot of drug. A relatively short course of liposomal amphotericin B (e.g., 1 to 3
doses) is all that is required to fully occupy these binding sites and result in persistent
antifungal activity. Further doses are simply redundant and only serve to increase the
probability of toxicity. The persistent occupation of receptors results in a sustained
antifungal response for many days, even after plasma concentrations have declined to
undetectable levels.
Exactly how liposomal amphotericin B trafﬁcs into the various clinically relevant
effect sites is not clear. The drug penetrates into CNS subcompartments that are
structurally normal and with histological evidence of inﬂammation (e.g., the ependyma
shown in Fig. 5D). The immunohistochemistry studies suggest that the transfer from
blood to the CNS occurs relatively quickly (i.e., in the ﬁrst 24 h), but they do not enable
estimates of the rate of transfer of drug. We did not observe high concentrations of
drug within cryptococcomas, where the blood-brain barrier is likely signiﬁcantly dis-
FIG 6 Time course of fungal density in the CSF of rabbits following various regimens of liposomal amphotericin B. Each line represents the data from a single
rabbit. Each animal received 5 mg/kg every 24 h. The time course of fungal density in the CSF in rabbits receiving a single dose of drug (B) is comparable to
that of controls (A). An abbreviated regimen of 5 mg/kg/day for three doses results in prompt fungicidal activity that is comparable to that achieved with daily
therapy with the same dose.
Abbreviated Induction for Cryptococcal Meningitis Antimicrobial Agents and Chemotherapy
June 2017 Volume 61 Issue 6 e00090-17 aac.asm.org 7
zac-aac/zac00617/zac6192d17z xppws S3 3/23/17 14:08 4/Color Fig: 3,4,5 ArtID: 00090-17 DOI:10.1128/AAC.00090-17CE: MAR
rupted, even though amphotericin B was readily quantiﬁable in homogenates of
cerebral tissue of mice. This is probably because the amphotericin B immunoassay is
relatively insensitive. We did not see any evidence of the drug being carried into
cryptococcomas by inﬂammatory cells (the dump truck phenomenon), as is described
for macrolides (18), although there was a very limited inﬂammatory response in this
model.
While the study provides the experimental foundation for the concept of using
abbreviated induction regimens of liposomal amphotericin B for cryptococcal menin-
gitis, there is some uncertainty about the best regimen(s) for humans. Taken in
isolation, the rabbit studies suggest that more than a single dose is required (with a
cumulative AUC of 833 mg · h/liter). The AUC associated with an i.v. dose of 5 mg/kg
in a rabbit is higher than that observed following administration of 20 mg/kg i.v. to
a mouse (833 versus 555 mg · h/liter, respectively), for which prolonged antifungal
activity in the cerebrum was observed (Fig. 1). Thus, the mouse studies may
underestimate the total (cumulative) drug exposure required for fungicidal activity
in humans. Estimates of appropriate regimens are further complicated by some
uncertainty in the PK of higher doses of liposomal amphotericin B in humans. We
recently described much greater drug exposures (maximum concentration of drug
in serum [Cmax] and AUC) after multiple doses in at least some children receiving up
to 10 mg/kg of LAMB (19), although we did not observe this phenomenon with
intermittent high doses in adults (20). Further detailed PK studies of higher doses
of LAMB are warranted.
The current study has several limitations and assumptions. First, we did not examine
whether immunological effectors may have had an antifungal effect in addition to that
of LAMB and whether this may have contributed to persistent antifungal activity
observed with single doses. There was no evidence from the histopathological studies
of an inﬂammatory inﬁltrate in either mice or rabbits (the latter is not shown). We
extensively investigated this possibility in a recent study that examined the effect of
abbreviated regimens of DAMB for cryptococcal meningoencephalitis, in which there
was no evidence of immune-mediated antifungal killing (13). Second, we made an
explicit assumption that the trafﬁcking (both the rate and extent) of drug from the
bloodstream to the site of infection is the same in mice, rabbits, and humans. Such an
assumption is central to PK-PD bridging studies for all drug-pathogen combinations. In
the majority of cases, this assumption is reasonable, but there are isolated examples
where it is not (21). Third, there remains a degree of uncertainty regarding the lowest
dose and shortest possible course of LAMB that is likely to be effective for patients with
cryptococcal meningoencephalitis. We did not design this study to speciﬁcally address
this question, which would have required many more animals. Finally, we did not
examine optimal combinations of antifungal agents when one or both agents is
administered as a short course.
Given the overwhelming cost and feasibility advantages of abbreviated induction
therapy based on one or few doses of LAMB, clinical trials are now required to further
test these ideas. A two-stage adaptive open-label phase II/III randomized noninferiority
trial comparing alternative short-course LAMB regimens is under way and will be
reported in 2017 (trial registration number ISRCTN10248064). These clinical trials will
provide information for new therapeutic options for this neglected infection.
MATERIALS AND METHODS
Strain and in vitro susceptibility testing. Cryptococcus neoformans var. grubii (ATCC 208821 or H99)
was the challenge organism for experiments in mice and rabbits. The MIC testing was performed using
European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Clinical and Laboratory
Standards Institute (CLSI) methodology. MICs were determined in three independently conducted
experiments.
Laboratory animal models of cryptococcal meningoencephalitis. All murine studies were per-
formed under UK Home Ofﬁce project license PPL 40/3630 and had received prior approval by the ethics
committee at the University of Liverpool. Two models of cryptococcal meningitis that provide comple-
mentary information on the time course of cryptococcal meningoencephalitis, and the response to
treatment with LAMB, were used. The murine model has the advantage of being highly reproducible. In
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this model, the fungal burden in the cerebrum is the primary readout and quantitative counts in the CSF
cannot be obtained. In contrast, the rabbit model enables the time course of fungal burden in the CSF,
which is a clinically relevant subcompartment within the central nervous system, to be determined. The
fungal burden in other central nervous system subcompartments is also available (e.g., cerebrum,
vitreous, meninges) but only at the time of sacriﬁce.
For the murine model, immunosuppression is not required because mice are inherently susceptible
to disseminated cryptococcal infection. An inoculum of 3 108 CFU in 0.25 ml phosphate-buffered saline
(PBS) was injected i.v. via the lateral tail vein, which results in a highly reproducible encephalitis. Mortality
occurs in the latter part of the second week of infection, meaning that early death does not confound
any assessment of fungal burden in the initial 7 to 10 days of infection. The intended inoculum was
conﬁrmed by using quantitative counts after each experiment. The limit of detection for quantitative
culture was 1.2 log10 CFU/g.
A rabbit model of cryptococcal meningoencephalitis that was originally developed and described by
Perfect et al. (15) was used to study the impact of abbreviated regimens on the time course of fungal
burden in the CSF. Brieﬂy, C. neoformans inocula were grown in yeast extract-peptone-dextrose (YPD)
broth to a ﬁnal concentration of (3  0.25)  108 CFU/ml. Inoculum concentrations were estimated by
optical density and conﬁrmed by quantitative culture. Anesthetized rabbits were infected via cisternal
injection with an inoculum volume of 0.3 ml. Rabbits were anesthetized at day 2, 5, 7, and 11
postinoculation. CSF was obtained via cisternal puncture. A 1-ml sample was removed at each time point.
All rabbits were sacriﬁced at the end of the experiment, which was 13 days postinoculation. A ﬁnal CSF
sample was obtained immediately after sacriﬁce. In addition, the fungal burden in the cerebrum at the
end of the study period was determined as an additional endpoint. Representative samples of cerebrum
were homogenized in 2 ml of PBS. Homogenate and CSF were then plated onto Sabouraud dextrose agar
(SDA) containing chloramphenicol.
PK-PD studies. The PK-PD relationships in mice were determined over the course of multiple,
independently conducted experiments. The time course of infection in the cerebrum was determined
using a destructive design in which groups of CD-1 mice (n  3 per group) were sacriﬁced at predeﬁned
intervals between 0 and 240 h postinoculation. Treatment was commenced 24 h postinoculation. Dose
ﬁnding studies were conducted using 0.5 to 20 mg/kg/day. Each experiment incorporated an untreated
control and at least two experimental arms (n  15 per arm). Each dosing regimen was repeated in
triplicate. Data from subjects requiring sacriﬁce on humane grounds were included in analyses at the
time of death.
The PK data in plasma and cerebrum were determined in a separate experiment and once the
relevant dose-response relationships had been determined. The PK was determined in infected mice. PK
data were obtained at two intervals (immediately following the initiation of therapy and then after 5 days
of dosing). Groups of mice (n  3) were sacriﬁced 0.5, 1, 2, 6, and 24 h after drug administration. Plasma
was obtained by terminal cardiac puncture, placed immediately on ice, centrifuged, and stored at80°C
for analysis. The cerebrum was extracted at the time of necropsy under sterile conditions. One hemi-
sphere was submitted for quantitative cultures, while the other was stored for future measurement of
amphotericin B concentrations.
PK-PD relationships were studied following various induction regimens, as follows. A single dose of
5 mg/kg was studied based on previous studies in invasive pulmonary aspergillosis. Groups of rabbits
received a single dose, 3 doses of 5 mg/kg/day, and daily therapy of 5 mg/kg/day.
Measurement of amphotericin B concentrations. The concentrations of amphotericin B were
estimated using a previously described assay (3). The limit of detection was 0.05 mg/liter. The intra- and
interday variation was 7%.
Histopathology and staining of LAMB in the CNS of mice. The brain was collected and placed into
10% neutral buffered formalin for histopathologic evaluation. Formalin-ﬁxed tissues were trimmed,
cryoprotected by sucrose replacement, and then embedded in OCT freezing medium. Approximately
5-m sections were prepared for staining.
A commercially available mouse monoclonal antibody directed against Cryptococcus neoformans was
used to determine the extent of infection (MyBioSource, LLC, San Diego, CA). Yeasts stained consistently
and intensely (4	) positive with the anti-C. neoformans antibody. The yeasts did not stain with the
species-, isotype-, and concentration-matched negative-control antibody (mouse IgG1) that was substi-
tuted for the mouse anti-C. neoformans reagent (data not shown).
Amphotericin B was visualized using an afﬁnity-puriﬁed rabbit anti-amphotericin B antibody (Anti-
bodies Inc., Davis, CA). Immunohistochemistry was performed using standard immunoperoxidase and
alkaline phosphatase methodology and validated by appropriate and reproducible positive and negative
controls for staining amphotericin B as previously described (22, 23).
Mathematical modeling. The murine PK and PD data from mice were modeled using a population
methodology with the program Pmetrics (24). The mean drug concentration, cerebral concentration, and
fungal burden in the cerebra from groups of three mice were used. All data were weighted by the
observed variance from each group of mice for drug concentrations and fungal burden. The structural
model took the form:
dX1
dt
 R1 CLSVC  Kcp Kcb X1 Kbc X3 Kpc X2 (1)
dX2
dt
Kpc X2 Kcp X1 (2)
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dX3
dt
 Kcb X1 Kbc X3 (3)
dN
dt
 Kg max1
X3
Hg
Vm
X3
Hg
Vm
 C50 g
Hg  1 NPopmax N (4)
where X1, X2, and X3 represent the amounts of amphotericin B (in milligrams) in the central compartment,
peripheral compartment, and cerebrum, respectively. N is the number of organisms in the cerebrum. R1
represents the i.v. injection of liposomal amphotericin B in milligrams; Kcb, Kbc, Kcp, and Kpc represent the
ﬁrst-order rate constants connecting the central (c), peripheral (p), and cerebrum (brain [b]) compart-
ments. Hg is the slope function for the suppression of growth. Kg max is the maximum rate of fungal
growth in the brain, Vm is the volume of the murine brain, Vc is the volume of the central compartment,
C50 g is the concentration of amphotericin B in the brain at which there is half-maximal inhibition of
growth, and Popmax is the maximum theoretical density of organisms in the brain.
Equation 1 describes the movement of liposomal amphotericin B into and out of the central
compartment (plasma). Equation 2 describes the movement of liposomal amphotericin B into and out of
the peripheral compartment. Equation 3 describes the movement of drug into the brain. Equation 4
describes the pharmacodynamics of amphotericin B. This equation contains terms that describe the
capacity-limited fungal growth in the brain and drug-induced suppression of the fungal growth.
The ﬁt of the mathematical model to the combined PK and PD data set from mice was assessed using
the log likelihood value, measures of precision and bias, visual inspection of the observed-versus-
predicted values both before and after the Bayesian step, and assessment of the linear regression of the
observer-versus-predicted values both before and after the Bayesian step. Inspection of the PK data of
liposomal amphotericin B in rabbits suggested that the volume of distribution contracted with time, as
recently described by us in children (19).
dX1
dt
 R1 CLSX3  Kcp X1 Kpc X2 (5)
dX2
dt
 Kcp X1 Kpc X2 (6)
dX3
dt
X3 K Vfin (7)
with output equation
Y1 X1 ⁄ X3 (8)
where X1 and X2 are the amounts of liposomal amphotericin B in the central and peripheral compart-
ments, respectively. CLS is the clearance of drug from the central compartment, and Kcp and Kpc are the
two ﬁrst-order intercompartmental rate constants connecting the central (c) and peripheral (p) com-
partments. X3 is the volume of the central compartment that contracts with time according to equation
7. X3 has an initial volume, Vini, which is estimated as an initial condition in Pmetrics. The volume
contracts over time according to the ﬁrst-order rate constant, K. The ﬁnal volume after prolonged drug
administration is Vﬁn. Y1 is ●●. Equation 5 describes the rate of change of the amount of liposomal
amphotericin B in the central compartment. Equation 6 describes the rate of change of the amount of
liposomal amphotericin B in the peripheral compartment.
PK-PD bridging studies. In order to place the experimental ﬁndings in a clinical context, we bridged
the preclinical PK-PD ﬁndings from mice and rabbits to patients using a previously described population
PK model for liposomal amphotericin B (20). This model was used to estimate the average drug exposure
(quantiﬁed in terms of AUC) resulting from various human doses.
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